Payment overview · 2025
General Payments
$1,890.99
116 reported records · 17 companies
Healthcare provider profile · identity verified
Georges S Yacoub, MD
Allopathic & Osteopathic Physicians|Internal Medicine · TROY, OH · NPI 1487659041
Verified facts
What the public records show
CMS Open Payments records show Georges S Yacoub, MD received $1,890.99 in general payments during 2025 across 116 reported records.
AstraZeneca Pharmaceuticals LP accounted for 23.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arikayce, Eliquis, Jardiance, Nucala, Trelegy Ellipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 197 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUCALA as an associated drug or biological on 100127 records involving 16970 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Nucala by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 364 claims for Trelegy Ellipta by this doctor in 2024.
Insmed, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Arikayce as an associated drug or biological on 32500 records involving 8305 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Arikayce by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $444.75 | 23.5% | 21 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $361.75 | 19.1% | 27 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $261.11 | 13.8% | 18 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $194.21 | 10.3% | 15 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $189.61 | 10.0% | 11 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $103.09 | 5.5% | 6 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $80.63 | 4.3% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $63.14 | 3.3% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $36.99 | 2.0% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.38 | 1.8% | 2 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $20.81 | 1.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.73 | 1.1% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $17.85 | 0.9% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $17.55 | 0.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.53 | 0.8% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $15.21 | 0.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.65 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,768.10 | 114 |
| Education | $122.89 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $427.93 | 28 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $280.27 | 21 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $224.61 | 8 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $215.82 | 8 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $194.21 | 15 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $148.49 | 4 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $148.33 | 4 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $103.09 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $81.48 | 6 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $80.63 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $63.14 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $35.01 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $28.13 | 2 | 2025 |
Source payment records
|
|||||
| AYVAKIT Normalized: ayvakit |
Biological | GENZYME CORPORATION | $22.79 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $22.62 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $20.81 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $20.81 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $20.73 | 1 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $17.85 | 1 | 2025 |
Source payment records
|
|||||
| SIMPONI Normalized: simponi |
Biological | Janssen Biotech, Inc. | $17.55 | 1 | 2025 |
Source payment records
|
|||||
| SIMPONI ARIA Normalized: simponi aria |
Biological | Janssen Biotech, Inc. | $17.55 | 1 | 2025 |
Source payment records
|
|||||
| STELARA Normalized: stelara |
Biological | Janssen Biotech, Inc. | $17.55 | 1 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $17.55 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.98 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.40 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.53 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $14.65 | 1 | 2025 |
Source payment records
|
|||||
| EBGLYSS Normalized: ebglyss |
Drug | Lilly USA, LLC | $14.37 | 1 | 2025 |
Source payment records
|
|||||
| TALTZ Normalized: taltz |
Drug | Lilly USA, LLC | $14.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Arikayce arikayce |
2025 | Arikayce | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 178 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 133 | exact normalized | Medicare Part D |
| NUCALA nucala |
2025 | Nucala | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 364 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
125 | 25 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
197 | 54 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
133 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | NUCALA open payments reported associated product |
CMS Open Payments — General Payments 100127 supporting records · 16970 recipient NPIs · example record 1190332378 |
Nucala · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
364 | 85 |
| Insmed, Inc. Exact reporting entity; no affiliate inference |
2025 | Arikayce open payments reported associated product |
CMS Open Payments — General Payments 32500 supporting records · 8305 recipient NPIs · example record 1186254431 |
Arikayce · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
133 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
84 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
178 | 37 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisone | Prednisone | 1671 | 355 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 1554 | 389 |
| Azithromycin | Azithromycin | 1202 | 261 |
| Atorvastatin Calcium | Atorvastatin Calcium | 583 | 135 |
| Omeprazole | Omeprazole | 475 | 95 |
| Montelukast Sodium | Montelukast Sodium | 467 | 80 |
| Fluticasone Propionate | Fluticasone Propionate | 445 | 149 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 423 | 90 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 364 | 85 |
| Gabapentin | Gabapentin | 351 | 75 |
| Amlodipine Besylate | Amlodipine Besylate | 346 | 78 |
| Metformin Hcl | Metformin Hcl | 340 | 78 |
| Furosemide | Furosemide | 327 | 78 |
| Pantoprazole Sodium | Pantoprazole Sodium | 323 | 84 |
| Levothyroxine Sodium | Levothyroxine Sodium | 310 | 73 |
| Lisinopril | Lisinopril | 297 | 66 |
| Breo Ellipta | Fluticasone/Vilanterol | 229 | 41 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 199 | 49 |
| Symbicort | Budesonide/Formoterol Fumarate | 197 | 54 |
| Trazodone Hcl | Trazodone Hcl | 195 | 41 |
| Cefuroxime | Cefuroxime Axetil | 183 | 139 |
| Metoprolol Tartrate | Metoprolol Tartrate | 182 | 48 |
| Eliquis | Apixaban | 178 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 174 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 173 | 40 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 170 | 53 |
| Alprazolam | Alprazolam | 161 | 26 |
| Losartan Potassium | Losartan Potassium | 155 | 33 |
| Jardiance | Empagliflozin | 133 | 20 |
| Buspirone Hcl | Buspirone Hcl | 130 | 33 |
| Farxiga | Dapagliflozin Propanediol | 125 | 25 |
| Potassium Chloride | Potassium Chloride | 124 | 30 |
| Simvastatin | Simvastatin | 113 | 26 |
| Ventolin Hfa | Albuterol Sulfate | 110 | 33 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 108 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 107 | 27 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 104 | 24 |
| Methylprednisolone | Methylprednisolone | 103 | 84 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 102 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 96 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 96 | 22 |
| Spiriva Respimat | Tiotropium Bromide | 95 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 95 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 94 | 22 |
| Celecoxib | Celecoxib | 89 | 26 |
| Nystatin | Nystatin | 85 | 36 |
| Trulicity | Dulaglutide | 84 | 18 |
| Dulera | Mometasone/Formoterol | 81 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 77 | 12 |
| Fenofibrate | Fenofibrate | 76 | 13 |
| Warfarin Sodium | Warfarin Sodium | 76 | suppressed |
| Glimepiride | Glimepiride | 73 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 72 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 72 | 16 |
| Sertraline Hcl | Sertraline Hcl | 69 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 68 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 67 | 20 |
| Allopurinol | Allopurinol | 64 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 64 | 17 |
| Fluconazole | Fluconazole | 63 | 23 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 60 | 16 |
| Bupropion Xl | Bupropion Hcl | 59 | 15 |
| Ozempic | Semaglutide | 58 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 57 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 57 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 56 | 14 |
| Tramadol Hcl | Tramadol Hcl | 56 | 22 |
| Famotidine | Famotidine | 54 | 16 |
| Lorazepam | Lorazepam | 53 | suppressed |
| Ondansetron Odt | Ondansetron | 51 | 20 |
| Carvedilol | Carvedilol | 50 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 49 | suppressed |
| Lidocaine | Lidocaine | 49 | 11 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 48 | 11 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 48 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 48 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 46 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 46 | 13 |
| Topiramate | Topiramate | 46 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 44 | suppressed |
| Clonazepam | Clonazepam | 43 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 43 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 42 | suppressed |
| Atenolol | Atenolol | 41 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | suppressed |
| Meloxicam | Meloxicam | 41 | 11 |
| Methocarbamol | Methocarbamol | 41 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 39 | 12 |
| Levofloxacin | Levofloxacin | 39 | 28 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | suppressed |
| Sucralfate | Sucralfate | 38 | 11 |
| Breyna | Budesonide/Formoterol Fumarate | 37 | 19 |
| Theophylline Er | Theophylline Anhydrous | 37 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 35 | 11 |
| Ibuprofen | Ibuprofen | 35 | suppressed |
| Linzess | Linaclotide | 34 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | 13 |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | suppressed |
| Glipizide Er | Glipizide | 32 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 32 | suppressed |
| Klor-Con M20 | Potassium Chloride | 32 | suppressed |
| Loperamide | Loperamide Hcl | 32 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 32 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 32 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 18 |
| Armodafinil | Armodafinil | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Roflumilast | Roflumilast | 28 | suppressed |
| Ubrelvy | Ubrogepant | 28 | suppressed |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Bumetanide | Bumetanide | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 18 |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Pentoxifylline | Pentoxifylline | 24 | suppressed |
| Ramipril | Ramipril | 23 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 20 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 19 | suppressed |
| Clarithromycin | Clarithromycin | 19 | 19 |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Metolazone | Metolazone | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | 12 |
| Diltiazem 24hr Er | Diltiazem Hcl | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 17 | suppressed |
| Triazolam | Triazolam | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Modafinil | Modafinil | 16 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Nucala | Mepolizumab | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 14 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 14 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Tobramycin | Tobramycin In 0.225% Sod Chlor | 14 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Paliperidone Er | Paliperidone | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 12 | suppressed |
| Dupixent Syringe | Dupilumab | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Arikayce | Amikacin Liposomal/Neb.Accessr | 11 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Niacin Er | Niacin | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,890.99 · 116 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AYVAKIT, Arikayce, BREZTRI, DUPIXENT, EBGLYSS, ELIQUIS, FASENRA, Flexitouch Plus, INSPIRE, JARDIANCE, NUCALA, NURTEC ODT, Nimbl, OFEV, SIMPONI, SIMPONI ARIA, STELARA, Sunosi, TALTZ, TEZSPIRE, TRELEGY ELLIPTA, TREMFYA, UBRELVY, VOQUEZNA, Vest Therapy Und, XYWAV, YUPELRI, ZAVZPRET, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arikayce play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error